However, as IKK and NF-κB–inducing kinase knockout or inhibitors have demonstrated significant toxicity (14–16), identification of other suitable therapeutic targets that inhibit aberrant activation of TNFα–NF-κB prosurvival signaling and enhance cancer cell cytotoxicity without such undesirable toxicities has been challenging. This evidence concerns the gene NFKB1 and cancer.